# Bavarian Nordic

Source: https://onco.cc/companies/bavarian-nordic/  
OnCo record `bavarian-nordic` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bavarian Nordic is a Danish vaccine company whose poxvirus-based prostate cancer vaccine PROSTVAC failed the phase 3 PROSPECT trial in 2017, after which it concentrated on infectious disease vaccines such as its smallpox and mpox vaccine.

## Summary

Bavarian Nordic, based in Hellerup near Copenhagen and listed on Nasdaq Copenhagen, built its business on the modified vaccinia Ankara platform. In cancer it developed PROSTVAC (rilimogene galvacirepvec), a vaccinia and fowlpox vaccine against prostate-specific antigen, which did not improve survival in the phase 3 PROSPECT trial in metastatic castration-resistant prostate cancer reported in 2017, and CV301, a vaccine against CEA and MUC1 tested with checkpoint inhibitors. The company now focuses on travel and public health vaccines. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Bavarian Nordic A/S
- Tags: ctgov-sponsor
- HQ: Hellerup
- Type: biotech
- Website: https://www.bavarian-nordic.com

## Sources

- Official website: https://www.bavarian-nordic.com
- ClinicalTrials.gov: trials led by Bavarian Nordic: https://clinicaltrials.gov/search?lead=Bavarian%20Nordic
- Wikipedia: https://en.wikipedia.org/wiki/Bavarian_Nordic

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)

---
JSON: https://onco.cc/api/v1/entities/bavarian-nordic.json